- Home
- GMAB vs FDS Comparison
GMAB vs FDS Comparison
Compare GMAB & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- FDS
- Stock Information
- Founded
- GMAB 1999
- FDS 1978
- Country
- GMAB Denmark
- FDS United States
- Employees
- GMAB N/A
- FDS N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- FDS Computer Software: Programming Data Processing
- Sector
- GMAB Health Care
- FDS Technology
- Exchange
- GMAB Nasdaq
- FDS Nasdaq
- Market Cap
- GMAB 17.4B
- FDS 17.6B
- IPO Year
- GMAB N/A
- FDS 1996
- Fundamental
- Price
- GMAB $29.93
- FDS $285.08
- Analyst Decision
- GMAB Strong Buy
- FDS Hold
- Analyst Count
- GMAB 7
- FDS 10
- Target Price
- GMAB $41.17
- FDS $356.78
- AVG Volume (30 Days)
- GMAB 3.1M
- FDS 767.2K
- Earning Date
- GMAB 11-06-2025
- FDS 09-18-2025
- Dividend Yield
- GMAB N/A
- FDS 1.54%
- EPS Growth
- GMAB 77.72
- FDS 11.79
- EPS
- GMAB 21.62
- FDS 15.55
- Revenue
- GMAB $3,646,881,232.00
- FDS $2,321,748,000.00
- Revenue This Year
- GMAB $24.25
- FDS $6.17
- Revenue Next Year
- GMAB $16.29
- FDS $5.44
- P/E Ratio
- GMAB $13.36
- FDS $18.35
- Revenue Growth
- GMAB 32.97
- FDS 5.39
- 52 Week Low
- GMAB $17.24
- FDS $272.50
- 52 Week High
- GMAB $33.65
- FDS $499.87
- Technical
- Relative Strength Index (RSI)
- GMAB 46.39
- FDS 38.48
- Support Level
- GMAB $29.57
- FDS $285.50
- Resistance Level
- GMAB $30.24
- FDS $296.80
- Average True Range (ATR)
- GMAB 0.67
- FDS 7.61
- MACD
- GMAB -0.58
- FDS 3.89
- Stochastic Oscillator
- GMAB 11.11
- FDS 48.91
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.